Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy?

Cancer Manag Res · 2018 · PMC5841349 · PMID 29535553

Europe PMC DOI

hedged sentences

0.6800

closest p · 13.6× alpha

0.6800

boldest claim

The sentences

failed to reach statistical significancep =0.68not close (p > 0.1)

Although bone marrow expression of Bax and Bcl-2 tended to remain higher among responders (median 1.01 and 0.29, respectively) as compared to non-responders (median 0.66 and 0.24, respectively), the difference failed to reach statistical significance ( U =784.5 and 733; p =0.68 and 0.28, respectively).

also in 6,035 other papers

did not reach statistical significanceno p-value reported

Overall, Bax and Bcl-2 were expressed higher among GR as compared to PR ( Figure 1 ) but did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.